General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Cine-Med Research Institute(MODEST), Protembis(SIGNIFICANT), Penumbra(SIGNIFICANT), Novartis(SIGNIFICANT), Ionis Pharma(MODEST), NovoNordisk(MODEST), Vectura(MODEST), VoxMedia(MODEST), Radcliffe(MODEST), Esperion Science(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Elixir Medical(MODEST), Stel(MODEST) OWNERSHIP/PARTNERSHIP/PRINCIPAL: CONTROLRAD(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Beth Israel Deaconess Medical Center(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), CSL Behring (SIGNIFICANT), Medtronic(SIGNIFICANT), OrbusNeich(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Concept Medical(SIGNIFICANT), Chiesi(SIGNIFICANT), CERC(SIGNIFICANT), Abiomed(SIGNIFICANT), Biosensors(SIGNIFICANT), Boston Scientific(SIGNIFICANT), Insel Gruppe AG(SIGNIFICANT), Philips(SIGNIFICANT), Arena(SIGNIFICANT), Idorsia Pharmaceuticals(MODEST), BAIM(SIGNIFICANT), Biotronik(MODEST), Janssen(SIGNIFICANT), Vivasure(MODEST), Alleviant Medical(SIGNIFICANT), Amgen Inc.(MODEST), Cytosorbents(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), PhaseBio(MODEST), Shockwave(MODEST), AtriCure(MODEST), RM Global(MODEST), Medtelligence(MODEST), Faraday Pharmaceuticals(SIGNIFICANT), Duke University(MODEST), Mediasphere(SIGNIFICANT), MJH Healthcare(MODEST), RenalPro(SIGNIFICANT), AM-Pharma(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), CardiaWave(SIGNIFICANT), CeloNova BioSciences(SIGNIFICANT), Humacyte(MODEST), Magenta(SIGNIFICANT), Zoll(SIGNIFICANT), Element Science(SIGNIFICANT), Affluent Medical(MODEST), MedAlliance(MODEST), MedScape(MODEST), Pi-Cardia(MODEST) OTHER FINANCIAL BENEFIT: WebMD(SIGNIFICANT)

View Full Disclosure